|[November 07, 2012]
CoLucid Pharmaceuticals to Attend the BIO-Europe 2012 Meeting in Hamburg, Germany
DURHAM, N.C. --(Business Wire)--
Pharmaceuticals, Inc., a privately held biopharmaceutical company,
announced today that Thomas P. Mathers, Chief Executive Officer, will be
attending the 18th Annual International Partnering Conference
held at the CCH (News - Alert) Congress Center in Hamburg, Germany from November 12-14,
Mr. Mathers, along with Linda Hogan, Vice President of Business
Development, will be meeting with potential partners to discuss the most
recent clinical and regulatory milestones achieved by CoLucid for
lasmiditan as well as highlights from recently completed market research.
"We have just completed two key market research activities-the first
study examines the percentage of migraine patients in the United States
who have concomitant risk factors for cardiovascular disease or
diagnosed disease, and further quantifies their level of risk of
suffering a cardiovascular event," said Mr. Mathers. He continues, "The
second market research study focuses on managed care organizations and
their potential positioning of asmiditan. Payers were very positive
regarding lasmiditan's development for migraine patients who do not
respond to triptan therapy or those who have risk factors for
cardiovascular disease where triptan therapy may not be appropriate."
is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed
to deliver efficacy in migraine without the vasoconstrictor activity
associated with previous generations of migraine therapies. Lasmiditan
is a member of a novel drug class called "ditans" and, unlike triptans,
penetrates the central nervous system (CNS) and selectively targets
5-HT1F receptors expressed in the trigeminal pathway. Lasmiditan does
not interact with vasoconstrictor 5-HT1B receptors activated by triptans.
Six clinical studies have been successfully completed, including a Phase
2b double blind, placebo controlled, oral, dose ranging study treating a
single migraine attack. In this Phase 2b study of 391 patients,
lasmiditan achieved its primary endpoint of reducing a moderate or
severe headache at baseline to mild or none 2 hours after dosing
(p<0.0001). Separation of individual doses from placebo was seen as
early as 30 minutes after dosing. Lasmiditan also achieved secondary
endpoints, including relief of nausea, photophobia and phonophobia.
Importantly, because there were no drug-related cardiovascular adverse
effects in the previous clinical studies, CoLucid expects the pivotal Ph
3 studies to confirm that lasmiditan's side effect profile is highly
differentiated from triptans and ergot derivatives.
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 by Pappas Ventures to advance innovative
drug candidates with the potential to provide safe and effective
treatment for CNS disorders. The company's investors include Pappas
Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds
and Triathlon Medical Ventures. For more information, please visit
CoLucid at www.colucid.com.
[ Back To Technology News's Homepage ]